- SK pharmteco has entered a strategic partnership with Prozomix to integrate a library of over 6,000 biocatalysts into its small molecule development and manufacturing services.
- The collaboration aims to support more efficient and sustainable API production by combining enzyme screening with global contract manufacturing capabilities.
SK pharmteco has announced a strategic partnership with Prozomix to incorporate biocatalysis capabilities into its small molecule development and contract manufacturing services.
Under the agreement, SK pharmteco will gain access to Prozomix’s “Biocatalysis Enzyme Toolkit,” which includes more than 6,000 native biocatalysts. These enzymes will be used across the company’s R&D centers in the United States, Europe, and Asia to support enzyme screening and identification for complex active pharmaceutical ingredient (API) synthesis.
The collaboration is intended to integrate enzyme discovery with process development and manufacturing, enabling a transition from early-stage screening to full-scale production. The companies stated that this approach supports more efficient and selective synthesis methods compared to traditional chemical processes.
Prozomix will contribute its enzyme discovery and scale-up capabilities, while SK pharmteco will apply its global manufacturing infrastructure to support development and commercial production. The partnership is expected to support pharmaceutical clients seeking alternative synthesis approaches for complex molecules.
“At SK pharmteco, our mission is to build strong relationships with industry leaders that are grounded in trust, quality, and shared commitment to delivering medicines reliably and to higher standards.”
Joerg Ahlgrimm, chief executive officer of SK pharmteco
